ADC Therapeutics SA Form 6-K Summary
Business Context and Reporting Period
ADC Therapeutics SA, a Swiss foreign private issuer, furnished this Form 6-K on February 6, 2023, reporting the completion of a public offering of the Company’s common shares by A.T. Holdings II Sàrl.
Transaction and Key Financial Metrics
- Shares offered: 12,000,000 common shares.
- Public offering price: $5.00 per share.
- Implied gross offering value: $60.0 million before underwriting discounts, commissions and expenses.
- Issuer proceeds: The filing identifies the transaction as a sale by A.T. Holdings II and does not state that ADC Therapeutics received proceeds from this offering.
- Financial results: The filing does not provide revenue, profit, cash flow, margin, debt, liquidity or operating guidance metrics.
Material Changes and Agreements
- On February 2, 2023, ADC Therapeutics entered into the Auven Agreement with A.T. Holdings II in connection with the offering.
- A.T. Holdings II agreed not to transfer or otherwise dispose of the Company’s shares or related securities until February 2, 2024, subject to specified exceptions, including the offering, certain affiliate or equity-holder transfers, pledges to Oaktree, foreclosure and change-of-control transactions.
- On February 6, 2023, ADC Therapeutics entered into the Oaktree Agreement with lenders and other counterparties associated with Oaktree.
- If A.T. Holdings II defaults and Oaktree forecloses on remaining pledged shares, ADC Therapeutics may be required, upon request and after the applicable restricted period, to register those shares for resale.
- The Oaktree counterparties agreed to restrictions on transferring the remaining shares until February 2, 2024, subject to specified exceptions.
- If ADC Therapeutics completes an underwritten primary equity financing generating at least $50 million of net proceeds during the restricted period, A.T. Holdings II and the Oaktree counterparties must provide customary 90-day lockups to the underwriters.
Outlook, Risks and Unusual Items
- The offering was a secondary sale by a major shareholder rather than a disclosed primary capital raise by ADC Therapeutics.
- Potential future resale of remaining shares following a default, foreclosure or registration could increase the public float and create selling pressure.
- The Company’s obligations include potential registration rights, related indemnification commitments and effectiveness requirements for a future resale registration statement.
- The filing contains no business outlook, clinical update, revenue forecast or liquidity forecast.
Investor Verification Items
- Verify whether ADC Therapeutics received any proceeds and confirm the net proceeds after underwriting discounts and expenses.
- Review the underwriting agreement, Auven Agreement and Oaktree Agreement for detailed transfer restrictions, exceptions and indemnification provisions.
- Determine the number of shares remaining pledged to Oaktree and the conditions that could trigger foreclosure or future registration rights.
- Assess the potential dilution or market impact from any future primary issuance or resale of remaining shares.
- Review subsequent filings for changes to the lockups, ownership positions, debt arrangements or registration rights.